ATAC PAK BUN REAGENT

K021385 · Elan Diagnostics · CDQ · Jul 12, 2002 · Clinical Chemistry

Device Facts

Record IDK021385
Device NameATAC PAK BUN REAGENT
ApplicantElan Diagnostics
Product CodeCDQ · Clinical Chemistry
Decision DateJul 12, 2002
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 862.1770
Device ClassClass 2

Intended Use

The ATAC PAK BUN Reagent Kit is intended for use with the ATAC 8000 Random Access Chemistry System for the quantitative determination of urea nitrogen in serum, plasma and urine. Urea nitrogen results are used in the diagnosis and treatment of certain renal and metabolic diseases. This reagent is intended to be used by trained personnel in a professional setting and is not intended for home use.

Device Story

The ATAC PAK BUN Reagent Kit is an in vitro diagnostic reagent used with the ATAC 8000 Random Access Chemistry System. It measures urea nitrogen in serum, plasma, and urine samples. The device utilizes an enzymatic reaction involving urease and glutamate dehydrogenase; the reaction causes a decrease in absorbance at 340 nm, which is measured by the chemistry system. The magnitude of the absorbance decrease is proportional to the urea nitrogen concentration. The system is operated by trained personnel in professional clinical laboratory settings. Results are provided to healthcare providers to assist in diagnosing and managing renal and metabolic conditions.

Clinical Evidence

Bench testing only. Linearity established from 2 to 100 mg/dL. Precision studies (n=60 per sample) showed within-run CVs of 1.3%–4.4% and total CVs of 1.7%–5.6%. Method comparison against a competitive reagent (n=217 for serum/plasma, n=92 for urine) showed high correlation (r=0.996 for serum/plasma; r=0.991 for urine). Detection limit is 2 mg/dL. Reagent and calibration stability confirmed for 14 days.

Technological Characteristics

Enzymatic reagent kit (urease and glutamate dehydrogenase). Measures urea nitrogen via spectrophotometric absorbance decrease at 340 nm. Designed for use on the ATAC 8000 Random Access Chemistry System. No specific materials of construction or software algorithm class (e.g., ML) are described; operation is based on standard clinical chemistry enzymatic principles.

Indications for Use

Indicated for the quantitative determination of urea nitrogen in serum, plasma, and urine in adult patients to aid in the diagnosis and treatment of renal and metabolic diseases. For professional use only; not for home use.

Regulatory Classification

Identification

A urea nitrogen test system is a device intended to measure urea nitrogen (an end-product of nitrogen metabolism) in whole blood, serum, plasma, and urine. Measurements obtained by this device are used in the diagnosis and treatment of certain renal and metabolic diseases.

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ JUL 12 2002 élan diagnostics Image /page/0/Picture/2 description: The image shows a logo for "élan". The logo features a stylized letter "e" formed by multiple concentric lines, with a wing-like extension on the left side. Below the symbol, the word "élan" is written in a lowercase, sans-serif font. The overall design is simple and modern. 021385 ## SUMMARY OF 510(K) SAFETY AND EFFECTIVENESS INFORMATION This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92. The ATAC PAK BUN Reagent Kit is intended for the quantitative determination of urea nitrogen in serum, plasma and urine. Urea nitrogen results are used in the diagnosis and treatment of certain renal and metabolic diseases. The ATAC PAK BUN Reagent determines urea nitrogen through the enzymatic action of urease and glutamate delydrogenase. The resulting decrease in absorbance at 340 nm is proportional to the urea nitrogen concentration of the sample. The ATAC PAK BUN Reagent Kit is substantially equivalent to the HiChem BUN Reagent Kit, product no. 88806, which is marketed by Elan Diagnostics Inc. of Brea California. The effectiveness of ATAC PAK BUN Reagent Kit on the ATAC 8000 Random Access Chemistry System is shown by the following studies. The recovery of urea nitrogen using the ATAC PAK BUN Reagent is linear from 2 to 100 mg/dL, as shown by the recovery of linearity standards that span the usable range. Regression statistics, which compare standard values, are shown below. (ATAC Recoveries) = 0.6 mg/dL + 0.9775 x (Standard Value), sy.x = 1.2 mg/dL, n = 50 Precision is demonstrated by the replicate assay of commercially available control serum. Precision statistics, calculated analogous to the method described in NCCLS Guideline EP3-T, are shown below. | Precision of BUN Recoveries in mg/dL | | | | | | | |--------------------------------------|------------|------|-------|------|-----|------| | | Within Run | | Total | | | | | Sample | n | mean | 1SD | %CV | 1SD | %CV | | Serum 1 | 60 | 7 | 0.3 | 4.4% | 0.4 | 5.6% | | Serum 2 | 60 | 34 | 0.5 | 1.5% | 0.8 | 2.3% | | Serum 3 | 60 | 61 | 0.9 | 1.4% | 1.1 | 1.9% | | Urine 1 | 60 | 21 | 0.4 | 2.1% | 0.5 | 2.5% | | Urine 2 | 60 | 80 | 1.0 | 1.3% | 1.4 | 1.7% | Mixed serum, plasma and diluted urine specimens, collected from adult patients, were assaved for urea nitrogen using the ATAC 8000 Random Access Chemistry System and another commercially available method. Results were compared by least squares linear regression and the following statistics were obtained. Serum/Plasma Comparison ATAC 8000 = 1.2 mg/dL + 0.977 x Competitive Reagent r = 0.996 n = 217 range = 5 - 100 mg/dL Urine Comparison ATAC 8000 = 1.9 mg/dL + 0.9525 x Competitive Reagent n = 92 range = 19 - 100 mg/dL r = 0.991 510(k) Notification, ATAC PAK BUN Reagent Kit, 29 April, 2002, p 45 Elan Diagnostics 1075 W. Lambert Road, Bldg. D · Brea California 92821 Phone: 714.672.3553 · Fax: 714.672.3554 Elan Diagnostics Is a division of Elan Pharmaceuticals {1}------------------------------------------------ The detection limit claim of 2 mg/dL is documented through the repetitive assay of a diluted serum control. The observed standard deviation of a 30 replicate within run precision study was 0 mg/dL. Consequently, the detection limit is reported as twice the round-off error of the assay. The 14 day on board reagent stability and 14 day calibration stability claims are documented through the assay of serum controls and urine pools over the claimed periods. In all cases, the total imprecision of urea nitrogen recoveries over the test periods are less than 3 mg/dL or 3%. Wigwam Stores Wyma Stocking Manager of Regulatory Affairs Elan Diagnostics {2}------------------------------------------------ Image /page/2/Picture/0 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized depiction of an eagle or bird-like figure with three curved lines forming its body and wings. The logo is encircled by the text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" in a circular arrangement. ## DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 2098 Gaither Road Rockville MD 20850 ## JUL 1 2 2002 Mr. Wynn Stocking Regulatory Affairs Manager Elan Diagnostics 1075 W. Lambert Road Brea, CA 92821 Re: k021385 > Trade/Device Name: ATAC PAK BUN Reagent Regulation Number: 21 CFR 862.1770 Regulation Name: Urea nitrogen test system Regulatory Class: Class II Product Code: CDQ Dated: April 29, 2002 Received: May 2, 2002 Dear Mr. Stocking: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. Iisting of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations. Title 21. Parts 800 to 898. In addition. FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050, {3}------------------------------------------------ Page 2 - This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and ' additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device. please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmaldsmamain.html". Sincerely yours, Steven Butman Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory-Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {4}------------------------------------------------ 510(k) Number (if known): . . K021385 ATAC PAK BUN Reagent Device Name: Indications for Use: The ATAC PAK BUN Reagent Kit is intended for use with the ATAC 8000 Random Access Chemistry System for the quandtative determination of urea nitrogen in serum, plasma and urine. Utea nitrogen results are used in the diagnosis and treatment of certain renal and metabolic diseases. This reagent is intended to be used by trained personnel in a professional setting and is not intended for home use. Elan Diagnostics July 9, 2002 Dan Cooper (Division Sign-Off) Division of Clinical Laboratory Devices 510(k) Number K021385 (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) Prescription Use (Per 21 CFR 801.109) OR Over-The-Counter Use __ (Optional Format 1-2-96)
Innolitics
510(k) Summary
Decision Summary
Classification Order
Enter a record ID and click Load to view the document.
100%